 |
인쇄하기
취소
|
AstraZenca's new drug for stroke conducting phase IIB study in Korea
AstraZeneca announced that the phase IIB study on the new drug for stroke (Stroke Acute Ischemic NXY-059 Treatment: SAINT) seems to be conducted for the first time in Korea.
The clinical study for NXY-059 (brand name: Cerovive) will be performed in 25 countries including Europe, America and Australia to assess its efficacy for stroke and safety against the total 3,400 patients.
In Asia th...
The clinical study for NXY-059 (brand name: Cerovive) will be performed in 25 countries including Europe, America and Australia to assess its efficacy for stroke and safety against the total 3,400 patients.
In Asia th...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.